| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 38 | 2018 | 386 | 4.590 |
Why?
|
| Myeloproliferative Disorders | 19 | 2016 | 155 | 2.900 |
Why?
|
| Leukemia, Myeloid, Acute | 33 | 2018 | 850 | 1.790 |
Why?
|
| World Health Organization | 20 | 2016 | 125 | 1.770 |
Why?
|
| Bone Marrow | 48 | 2018 | 421 | 1.720 |
Why?
|
| Chromosome Aberrations | 39 | 2012 | 353 | 1.480 |
Why?
|
| Leukemia | 20 | 2017 | 309 | 1.250 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 10 | 2009 | 177 | 1.150 |
Why?
|
| Leukemia, Hairy Cell | 31 | 1994 | 73 | 1.030 |
Why?
|
| Leukemia, Myeloid | 25 | 2016 | 241 | 1.010 |
Why?
|
| Primary Myelofibrosis | 13 | 2010 | 72 | 0.960 |
Why?
|
| Lymphoma | 14 | 2009 | 255 | 0.890 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2009 | 111 | 0.670 |
Why?
|
| Polycythemia Vera | 7 | 2009 | 22 | 0.600 |
Why?
|
| Thrombocythemia, Essential | 6 | 2009 | 18 | 0.560 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 87 | 0.560 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 100 | 0.520 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2018 | 682 | 0.510 |
Why?
|
| Azacitidine | 1 | 2018 | 152 | 0.510 |
Why?
|
| Humans | 188 | 2019 | 98370 | 0.490 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 39 | 0.490 |
Why?
|
| Trans-Activators | 3 | 2018 | 447 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 671 | 0.440 |
Why?
|
| Translocation, Genetic | 21 | 2014 | 246 | 0.430 |
Why?
|
| Acute Disease | 26 | 2017 | 860 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 1999 | 262 | 0.410 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 2381 | 0.400 |
Why?
|
| Blood Cells | 4 | 2012 | 32 | 0.390 |
Why?
|
| Hypergammaglobulinemia | 1 | 2013 | 7 | 0.390 |
Why?
|
| Erythropoiesis | 4 | 2011 | 53 | 0.390 |
Why?
|
| Histiocytosis, Sinus | 1 | 2013 | 17 | 0.390 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 2 | 2009 | 12 | 0.380 |
Why?
|
| Plasma Cells | 1 | 2013 | 91 | 0.370 |
Why?
|
| Hodgkin Disease | 6 | 1998 | 144 | 0.350 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2012 | 444 | 0.340 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 480 | 0.330 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 19 | 0.330 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 261 | 0.330 |
Why?
|
| Histones | 1 | 2013 | 364 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 8 | 6 | 2004 | 83 | 0.320 |
Why?
|
| Prognosis | 34 | 2014 | 4126 | 0.320 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 358 | 0.300 |
Why?
|
| Karyotyping | 36 | 2006 | 220 | 0.300 |
Why?
|
| Male | 102 | 2015 | 47263 | 0.300 |
Why?
|
| Mutation | 10 | 2009 | 4428 | 0.290 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 589 | 0.280 |
Why?
|
| Chromosome Disorders | 11 | 1995 | 98 | 0.280 |
Why?
|
| Genome, Human | 2 | 2013 | 834 | 0.280 |
Why?
|
| Diagnosis, Differential | 12 | 2009 | 1570 | 0.270 |
Why?
|
| Lymphoproliferative Disorders | 6 | 2000 | 105 | 0.270 |
Why?
|
| Female | 96 | 2019 | 51761 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2014 | 2661 | 0.270 |
Why?
|
| Cytarabine | 10 | 2012 | 218 | 0.270 |
Why?
|
| Middle Aged | 85 | 2019 | 29532 | 0.270 |
Why?
|
| Hematologic Neoplasms | 7 | 2015 | 383 | 0.260 |
Why?
|
| Aged | 71 | 2014 | 21844 | 0.260 |
Why?
|
| Blast Crisis | 4 | 2008 | 37 | 0.250 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 553 | 0.250 |
Why?
|
| Adult | 89 | 2014 | 29587 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 21 | 6 | 2004 | 53 | 0.240 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2003 | 150 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 5 | 5 | 2009 | 113 | 0.220 |
Why?
|
| Interferon Type I | 10 | 1992 | 170 | 0.220 |
Why?
|
| Methylation | 2 | 2018 | 294 | 0.210 |
Why?
|
| Terminology as Topic | 3 | 2012 | 225 | 0.200 |
Why?
|
| Algorithms | 4 | 2009 | 2003 | 0.200 |
Why?
|
| Burkitt Lymphoma | 3 | 2004 | 32 | 0.200 |
Why?
|
| Trisomy | 6 | 2002 | 53 | 0.200 |
Why?
|
| Guidelines as Topic | 3 | 2012 | 169 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2016 | 137 | 0.190 |
Why?
|
| Daunorubicin | 7 | 2012 | 77 | 0.180 |
Why?
|
| Interferon-alpha | 5 | 1994 | 191 | 0.180 |
Why?
|
| Adolescent | 29 | 2014 | 10140 | 0.180 |
Why?
|
| Lymphatic Diseases | 3 | 2013 | 31 | 0.180 |
Why?
|
| Antigens, Neoplasm | 5 | 1990 | 365 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 2 | 2009 | 191 | 0.170 |
Why?
|
| Survival Analysis | 12 | 2008 | 1529 | 0.160 |
Why?
|
| Aged, 80 and over | 19 | 2014 | 7418 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 3 | 2003 | 244 | 0.160 |
Why?
|
| Chromosomes, Human, 16-18 | 7 | 1984 | 16 | 0.160 |
Why?
|
| Composite Lymphoma | 1 | 2019 | 2 | 0.150 |
Why?
|
| Cell Lineage | 5 | 2016 | 332 | 0.150 |
Why?
|
| Chromosome Inversion | 6 | 2014 | 45 | 0.150 |
Why?
|
| Chromosome Deletion | 10 | 2009 | 218 | 0.150 |
Why?
|
| Lymph Nodes | 10 | 2013 | 563 | 0.150 |
Why?
|
| Classification | 3 | 2006 | 60 | 0.140 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2018 | 80 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 2 | 1998 | 286 | 0.140 |
Why?
|
| Mastocytosis | 3 | 2016 | 14 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 1995 | 100 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2008 | 80 | 0.140 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 3 | 0.140 |
Why?
|
| Histiocytes | 2 | 1998 | 22 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 7 | 0.140 |
Why?
|
| GATA1 Transcription Factor | 1 | 2018 | 20 | 0.140 |
Why?
|
| Antigens, Differentiation | 4 | 1991 | 126 | 0.130 |
Why?
|
| Etoposide | 6 | 2010 | 207 | 0.130 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 63 | 0.130 |
Why?
|
| Hematopoiesis | 5 | 2015 | 187 | 0.130 |
Why?
|
| Child, Preschool | 9 | 2013 | 4042 | 0.130 |
Why?
|
| Remission Induction | 12 | 2012 | 764 | 0.130 |
Why?
|
| Bone Marrow Examination | 6 | 2009 | 40 | 0.130 |
Why?
|
| Cytosine | 1 | 2018 | 124 | 0.130 |
Why?
|
| Infant | 3 | 2013 | 3361 | 0.120 |
Why?
|
| Hematopoietic System | 3 | 2009 | 12 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2008 | 369 | 0.120 |
Why?
|
| Spleen | 7 | 2001 | 376 | 0.120 |
Why?
|
| Methyltransferases | 1 | 2018 | 220 | 0.120 |
Why?
|
| Anemia | 3 | 2009 | 135 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2014 | 977 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 565 | 0.120 |
Why?
|
| Philadelphia Chromosome | 1 | 1996 | 48 | 0.120 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 7 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1993 | 114 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 22 | 4 | 2004 | 41 | 0.110 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1995 | 7 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 420 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2009 | 1775 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2018 | 1721 | 0.110 |
Why?
|
| Eosinophilia | 3 | 2016 | 87 | 0.110 |
Why?
|
| Preleukemia | 2 | 2009 | 10 | 0.110 |
Why?
|
| Child | 13 | 2013 | 7750 | 0.110 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2014 | 9 | 0.100 |
Why?
|
| Chromatin | 1 | 2018 | 461 | 0.100 |
Why?
|
| Chromosomes, Human, 6-12 and X | 6 | 1986 | 13 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 222 | 0.100 |
Why?
|
| Abnormal Karyotype | 1 | 2014 | 8 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 638 | 0.100 |
Why?
|
| Protein Binding | 1 | 2018 | 1561 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 1998 | 306 | 0.100 |
Why?
|
| Splenectomy | 7 | 1988 | 50 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 34 | 0.100 |
Why?
|
| Bone Marrow Cells | 7 | 2015 | 270 | 0.100 |
Why?
|
| Alkaline Phosphatase | 5 | 1988 | 129 | 0.100 |
Why?
|
| Leukocyte Count | 10 | 2015 | 215 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 117 | 0.100 |
Why?
|
| Methotrexate | 2 | 2012 | 229 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 118 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 755 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2012 | 464 | 0.100 |
Why?
|
| Megakaryocytes | 4 | 2008 | 39 | 0.100 |
Why?
|
| Sclerosis | 1 | 2013 | 30 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2014 | 1568 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2008 | 331 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2004 | 81 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 139 | 0.090 |
Why?
|
| Cyclosporins | 2 | 2010 | 56 | 0.090 |
Why?
|
| Mastocytosis, Systemic | 2 | 2009 | 13 | 0.090 |
Why?
|
| T-Lymphocytes | 6 | 2014 | 1334 | 0.090 |
Why?
|
| Vidarabine | 2 | 2003 | 107 | 0.090 |
Why?
|
| Anemia, Refractory | 3 | 1996 | 5 | 0.090 |
Why?
|
| Janus Kinase 2 | 2 | 2009 | 59 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2004 | 88 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2013 | 722 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 301 | 0.090 |
Why?
|
| fas Receptor | 1 | 2012 | 73 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2005 | 284 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2896 | 0.090 |
Why?
|
| Neutropenia | 3 | 2007 | 211 | 0.090 |
Why?
|
| Splenomegaly | 3 | 2004 | 19 | 0.090 |
Why?
|
| Recombinant Proteins | 11 | 1996 | 994 | 0.090 |
Why?
|
| Erythropoietin | 3 | 1997 | 90 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 1997 | 158 | 0.080 |
Why?
|
| Biopsy | 8 | 2014 | 1225 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 244 | 0.080 |
Why?
|
| Leukemia, Monocytic, Acute | 3 | 1987 | 9 | 0.080 |
Why?
|
| Follow-Up Studies | 13 | 2014 | 4044 | 0.080 |
Why?
|
| Survival Rate | 6 | 2012 | 2050 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 1268 | 0.080 |
Why?
|
| Interferons | 3 | 1990 | 114 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2013 | 2009 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 12 | 0.080 |
Why?
|
| Gene Expression | 2 | 2009 | 1322 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 27 | 0.080 |
Why?
|
| Eosinophils | 3 | 1986 | 196 | 0.080 |
Why?
|
| Hematinics | 1 | 2009 | 12 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 54 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2001 | 79 | 0.070 |
Why?
|
| Treatment Outcome | 15 | 2010 | 9770 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 2017 | 0.070 |
Why?
|
| Thalidomide | 1 | 2009 | 57 | 0.070 |
Why?
|
| Topotecan | 1 | 2009 | 47 | 0.070 |
Why?
|
| Cell Count | 1 | 2009 | 195 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 2 | 1987 | 116 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 305 | 0.070 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2008 | 9 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 98 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 1988 | 291 | 0.070 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 1985 | 106 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 568 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2012 | 104 | 0.070 |
Why?
|
| Chlorambucil | 2 | 1984 | 13 | 0.070 |
Why?
|
| Drug Administration Schedule | 7 | 2009 | 837 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2070 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 1992 | 28 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2007 | 6 | 0.060 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2007 | 5 | 0.060 |
Why?
|
| Disease-Free Survival | 5 | 2012 | 1195 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2007 | 33 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2006 | 1116 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 5 | 1992 | 48 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2577 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2018 | 3633 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 608 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2014 | 55 | 0.060 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 74 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 105 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2007 | 156 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2007 | 988 | 0.060 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Thrombocytosis | 2 | 1996 | 9 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2004 | 81 | 0.060 |
Why?
|
| Bone Marrow Diseases | 4 | 2015 | 38 | 0.060 |
Why?
|
| Cisplatin | 1 | 1987 | 578 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 660 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2002 | 106 | 0.050 |
Why?
|
| Lung Neoplasms | 4 | 1987 | 2471 | 0.050 |
Why?
|
| Mice | 5 | 2015 | 12735 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1817 | 0.050 |
Why?
|
| Neutrophils | 6 | 1997 | 346 | 0.050 |
Why?
|
| Cladribine | 1 | 2003 | 30 | 0.050 |
Why?
|
| Fibrosis | 2 | 1996 | 234 | 0.050 |
Why?
|
| Base Sequence | 4 | 2012 | 2224 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2002 | 51 | 0.050 |
Why?
|
| Skin Diseases | 1 | 1984 | 178 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2012 | 1752 | 0.050 |
Why?
|
| Leukemia, B-Cell | 1 | 2002 | 22 | 0.050 |
Why?
|
| Europe | 2 | 2001 | 357 | 0.050 |
Why?
|
| Chromosomes, Human, 13-15 | 4 | 1985 | 18 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1982 | 20 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 2574 | 0.040 |
Why?
|
| Liver | 5 | 1989 | 1230 | 0.040 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1981 | 11 | 0.040 |
Why?
|
| Anemia, Aplastic | 3 | 2015 | 34 | 0.040 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 25 | 0.040 |
Why?
|
| Staining and Labeling | 6 | 2001 | 161 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2001 | 130 | 0.040 |
Why?
|
| Retrospective Studies | 11 | 2008 | 11043 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1992 | 64 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 159 | 0.040 |
Why?
|
| Antigens, CD | 3 | 1991 | 484 | 0.040 |
Why?
|
| Ki-1 Antigen | 2 | 1990 | 19 | 0.040 |
Why?
|
| Phenotype | 3 | 2015 | 2667 | 0.040 |
Why?
|
| Lymphocytes | 4 | 1995 | 461 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1998 | 196 | 0.040 |
Why?
|
| Hepatitis C | 1 | 1982 | 186 | 0.040 |
Why?
|
| Disease Progression | 3 | 2006 | 1615 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2001 | 68 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 1945 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 2 | 1996 | 8 | 0.040 |
Why?
|
| International Cooperation | 1 | 2000 | 132 | 0.040 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 1998 | 21 | 0.030 |
Why?
|
| Multivariate Analysis | 4 | 2006 | 1010 | 0.030 |
Why?
|
| Time Factors | 7 | 2003 | 5577 | 0.030 |
Why?
|
| Animals | 5 | 2015 | 28981 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2009 | 4818 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1998 | 110 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 889 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 4 | 2002 | 1419 | 0.030 |
Why?
|
| Platelet Count | 3 | 1989 | 94 | 0.030 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 3 | 1985 | 6 | 0.030 |
Why?
|
| Blotting, Southern | 2 | 1994 | 107 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 1995 | 228 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1998 | 355 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 1785 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.030 |
Why?
|
| Age Factors | 3 | 2008 | 1974 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 1996 | 5 | 0.030 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 162 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 13 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2016 | 54 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2015 | 17 | 0.030 |
Why?
|
| Drug Therapy, Combination | 5 | 1997 | 765 | 0.030 |
Why?
|
| Chromosomes, Human, 19-20 | 3 | 1986 | 4 | 0.030 |
Why?
|
| Chromosome Banding | 6 | 1991 | 66 | 0.030 |
Why?
|
| Leukemia, Mast-Cell | 2 | 2008 | 5 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 2897 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 121 | 0.030 |
Why?
|
| Aziridines | 2 | 2005 | 10 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 1994 | 894 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 90 | 0.030 |
Why?
|
| Benzoquinones | 2 | 2005 | 27 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 68 | 0.030 |
Why?
|
| Young Adult | 3 | 2014 | 7568 | 0.030 |
Why?
|
| Mitoxantrone | 2 | 2005 | 65 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1994 | 14 | 0.030 |
Why?
|
| Cytogenetic Analysis | 2 | 2006 | 70 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1991 | 19 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1994 | 22 | 0.030 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 18 | 0.030 |
Why?
|
| Decision Making | 1 | 2000 | 689 | 0.030 |
Why?
|
| Splenic Neoplasms | 1 | 1994 | 17 | 0.030 |
Why?
|
| Chromosomes, Human, 4-5 | 2 | 1986 | 7 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2014 | 83 | 0.030 |
Why?
|
| Acid Phosphatase | 4 | 1988 | 28 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 135 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2007 | 554 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1993 | 7 | 0.030 |
Why?
|
| HTLV-I Infections | 1 | 1993 | 5 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 1397 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1994 | 246 | 0.020 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 90 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 1994 | 110 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 1992 | 33 | 0.020 |
Why?
|
| Infusions, Intravenous | 3 | 2003 | 403 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2004 | 62 | 0.020 |
Why?
|
| Digestive System | 2 | 1984 | 42 | 0.020 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2012 | 20 | 0.020 |
Why?
|
| Gene Rearrangement | 2 | 1990 | 175 | 0.020 |
Why?
|
| Incidence | 2 | 1994 | 1787 | 0.020 |
Why?
|
| Animal Diseases | 1 | 1992 | 5 | 0.020 |
Why?
|
| Cell Division | 2 | 1990 | 690 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2012 | 78 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 917 | 0.020 |
Why?
|
| Blood Cell Count | 4 | 1987 | 68 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2014 | 615 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 156 | 0.020 |
Why?
|
| Neoplasms | 3 | 2004 | 3349 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1990 | 16 | 0.020 |
Why?
|
| Lymphocytosis | 1 | 1990 | 11 | 0.020 |
Why?
|
| Recurrence | 2 | 2004 | 1264 | 0.020 |
Why?
|
| Heterozygote | 1 | 1992 | 392 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1991 | 127 | 0.020 |
Why?
|
| Animals, Zoo | 1 | 1992 | 83 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2212 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1990 | 51 | 0.020 |
Why?
|
| Histocytochemistry | 3 | 1984 | 122 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1990 | 78 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 251 | 0.020 |
Why?
|
| Basophils | 2 | 1985 | 26 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1990 | 220 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1988 | 226 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 1985 | 60 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1094 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1990 | 453 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 180 | 0.020 |
Why?
|
| Risk Factors | 3 | 2004 | 6273 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2005 | 923 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 208 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2008 | 156 | 0.020 |
Why?
|
| Microscopy, Electron | 3 | 1983 | 435 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 320 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 100 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 676 | 0.020 |
Why?
|
| Cytogenetics | 2 | 1991 | 27 | 0.020 |
Why?
|
| Kidney | 2 | 1984 | 1121 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1992 | 195 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1994 | 3228 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2009 | 371 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2858 | 0.020 |
Why?
|
| Interphase | 3 | 1991 | 36 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2008 | 226 | 0.020 |
Why?
|
| Cat-Scratch Disease | 1 | 1986 | 1 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1986 | 11 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2003 | 2085 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 1991 | 1539 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 1986 | 37 | 0.010 |
Why?
|
| United States | 1 | 2000 | 8262 | 0.010 |
Why?
|
| Multiple Myeloma | 2 | 2000 | 372 | 0.010 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1986 | 25 | 0.010 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1985 | 19 | 0.010 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2005 | 17 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 34 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1989 | 1064 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2007 | 679 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2003 | 970 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1145 | 0.010 |
Why?
|
| Random Allocation | 2 | 1987 | 312 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 307 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 1752 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 1160 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1790 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 400 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 302 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 20 | 0.010 |
Why?
|
| Lymphokines | 1 | 1984 | 74 | 0.010 |
Why?
|
| Leukopenia | 1 | 1984 | 66 | 0.010 |
Why?
|
| Phagocytosis | 3 | 1980 | 118 | 0.010 |
Why?
|
| Autopsy | 1 | 1984 | 131 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3616 | 0.010 |
Why?
|
| Aneuploidy | 2 | 1981 | 60 | 0.010 |
Why?
|
| Osteolysis | 1 | 1984 | 10 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1984 | 42 | 0.010 |
Why?
|
| Respiratory System | 1 | 1984 | 120 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1984 | 60 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 128 | 0.010 |
Why?
|
| Neck | 1 | 1984 | 103 | 0.010 |
Why?
|
| Granulocytes | 1 | 1983 | 34 | 0.010 |
Why?
|
| Hematocrit | 1 | 1983 | 68 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 743 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 260 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 221 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 246 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 79 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 471 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1982 | 95 | 0.010 |
Why?
|
| Organ Size | 1 | 1983 | 370 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 307 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 281 | 0.010 |
Why?
|
| Rituximab | 1 | 2002 | 136 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1982 | 58 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2001 | 31 | 0.010 |
Why?
|
| Tryptases | 1 | 2001 | 11 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 2001 | 6 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 2001 | 22 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 397 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2001 | 15 | 0.010 |
Why?
|
| Viscera | 1 | 2001 | 19 | 0.010 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2001 | 8 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 415 | 0.010 |
Why?
|
| Mast Cells | 1 | 2001 | 97 | 0.010 |
Why?
|
| Clone Cells | 1 | 2001 | 223 | 0.010 |
Why?
|
| Skin | 2 | 2001 | 591 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 1276 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2001 | 136 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 168 | 0.010 |
Why?
|
| North America | 1 | 2001 | 210 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 642 | 0.010 |
Why?
|
| Syndrome | 1 | 1981 | 442 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 154 | 0.010 |
Why?
|
| Immunologic Capping | 1 | 1980 | 10 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 154 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2001 | 165 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 272 | 0.010 |
Why?
|
| Age of Onset | 1 | 2001 | 369 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 402 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1991 | 234 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1989 | 109 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 722 | 0.010 |
Why?
|
| Reticulin | 1 | 1978 | 2 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1947 | 0.010 |
Why?
|
| Sex Factors | 1 | 1982 | 1142 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1978 | 11 | 0.010 |
Why?
|
| B-Lymphocytes | 3 | 1991 | 731 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1981 | 325 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 1163 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2004 | 2056 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1996 | 28 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 297 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 46 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 136 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 317 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 1975 | 9 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2023 | 0.010 |
Why?
|
| Monosomy | 1 | 1995 | 12 | 0.010 |
Why?
|
| Abdomen | 1 | 1975 | 121 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1975 | 173 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1975 | 187 | 0.010 |
Why?
|
| Biomarkers | 1 | 2001 | 2021 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 72 | 0.010 |
Why?
|
| Brain | 1 | 1984 | 2439 | 0.010 |
Why?
|
| Cytoplasmic Granules | 3 | 1980 | 97 | 0.010 |
Why?
|
| Monocytes | 2 | 1985 | 220 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 2579 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1993 | 201 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1992 | 9 | 0.010 |
Why?
|
| DNA Primers | 1 | 1993 | 530 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 239 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 557 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1992 | 89 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1993 | 238 | 0.010 |
Why?
|
| Bufonidae | 1 | 1992 | 2 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1988 | 1126 | 0.010 |
Why?
|
| Hedgehogs | 1 | 1992 | 2 | 0.010 |
Why?
|
| Lions | 1 | 1992 | 3 | 0.010 |
Why?
|
| Lung | 1 | 1979 | 1408 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 145 | 0.010 |
Why?
|
| Snakes | 1 | 1992 | 16 | 0.010 |
Why?
|
| CD11 Antigens | 1 | 1991 | 14 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1991 | 13 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 1991 | 35 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1991 | 110 | 0.010 |
Why?
|
| Pentostatin | 1 | 1990 | 13 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1992 | 890 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1992 | 325 | 0.010 |
Why?
|
| X Chromosome | 1 | 1991 | 154 | 0.000 |
Why?
|
| Fluorescent Dyes | 1 | 1992 | 257 | 0.000 |
Why?
|
| Genes, Immunoglobulin | 1 | 1990 | 62 | 0.000 |
Why?
|
| DNA Probes | 1 | 1990 | 67 | 0.000 |
Why?
|
| Lymphoma, Follicular | 1 | 1990 | 73 | 0.000 |
Why?
|
| Birds | 1 | 1992 | 180 | 0.000 |
Why?
|
| Metaphase | 2 | 1980 | 20 | 0.000 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 1980 | 29 | 0.000 |
Why?
|
| DNA, Neoplasm | 1 | 1990 | 267 | 0.000 |
Why?
|
| Centromere | 1 | 1988 | 28 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1989 | 198 | 0.000 |
Why?
|
| Leukocytes | 2 | 1980 | 214 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1986 | 14 | 0.000 |
Why?
|
| Francisella | 1 | 1986 | 1 | 0.000 |
Why?
|
| Haemophilus | 1 | 1986 | 1 | 0.000 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1986 | 8 | 0.000 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1986 | 12 | 0.000 |
Why?
|
| Antitubercular Agents | 1 | 1986 | 63 | 0.000 |
Why?
|
| Erythrocyte Transfusion | 1 | 1986 | 82 | 0.000 |
Why?
|
| Mitosis | 2 | 1976 | 152 | 0.000 |
Why?
|
| Lymphopenia | 1 | 1985 | 31 | 0.000 |
Why?
|
| Colony-Stimulating Factors | 1 | 1984 | 13 | 0.000 |
Why?
|
| Immune Sera | 1 | 1984 | 48 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1986 | 179 | 0.000 |
Why?
|
| Interleukin-3 | 1 | 1984 | 39 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1984 | 51 | 0.000 |
Why?
|
| Thymidine | 1 | 1984 | 58 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 1275 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1986 | 160 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1984 | 146 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1985 | 194 | 0.000 |
Why?
|
| Retroviridae Infections | 1 | 1984 | 43 | 0.000 |
Why?
|
| Mutagens | 1 | 1982 | 30 | 0.000 |
Why?
|
| Insecticides | 1 | 1982 | 26 | 0.000 |
Why?
|
| Solvents | 1 | 1982 | 91 | 0.000 |
Why?
|
| Metals | 1 | 1982 | 105 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1981 | 145 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1981 | 73 | 0.000 |
Why?
|
| Zymosan | 1 | 1980 | 2 | 0.000 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1980 | 3 | 0.000 |
Why?
|
| Lectins | 1 | 1980 | 82 | 0.000 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 1980 | 5 | 0.000 |
Why?
|
| Tartrates | 1 | 1980 | 5 | 0.000 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1980 | 22 | 0.000 |
Why?
|
| Butyrates | 1 | 1980 | 62 | 0.000 |
Why?
|
| Quinacrine | 1 | 1978 | 10 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1978 | 45 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1978 | 28 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1980 | 258 | 0.000 |
Why?
|
| Sex Chromosomes | 1 | 1978 | 57 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1978 | 40 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1980 | 676 | 0.000 |
Why?
|
| Quinacrine Mustard | 1 | 1976 | 1 | 0.000 |
Why?
|
| Chromosomes | 1 | 1976 | 91 | 0.000 |
Why?
|
| Macrophages | 1 | 1975 | 643 | 0.000 |
Why?
|